Morgans says these 4 ASX 300 stocks are post-results buys

The broker was pleased with these results. Here's what you need to know.

| More on:
Two smiling work colleagues discuss an investment or business plan at their office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The team at Morgans has been running the rule over recent result releases.

Four ASX 300 stocks that were given the thumbs up and are described as "compelling buying prospects right now" are named below. Here's what its analysts are saying about them:

Challenger Ltd (ASX: CGF) 

The first ASX 300 stock that analysts at Morgans are positive on is annuities company Challenger. It was pleased with its result and highlights its improved capital position. It said:

CGF's FY24 normalised NPAT (A$417m) was in-line with consensus and +14% on the pcp. Overall, we saw this as a positive FY24 result highlighted by a strong improvement in Life business margins/returns, good group cost control and an upward step change in CGF's capital position. We retain our Add rating.

Its analysts have retained their add rating with an improved price target of $8.66.

CSL Ltd (ASX: CSL)

Morgans notes that this biotherapeutics giant delivered a result in line with expectations thanks largely to the key CSL Behring business. It commented:

FY24 results were broadly in line, with double-digit underlying top and bottom line growth and strong OCF. Strong plasma collections drove Behring sales (+15%), while Seqirus was soft (+4%) on reduced immunisation rates, albeit above market, and Vifor grew modestly given follow-on products in some EU markets. We retain our Add rating.

Morgans has retained its add rating with an improved price target of $330.75.

James Hardie Industries plc (ASX: JHX)

Another ASX 300 stock that Morgans remains positive on is building materials company James Hardie. The broker was disappointed with its second quarter guidance but notes that management has reaffirmed its full year guidance. It said:

JHX has reiterated its FY25 guidance, while forecasting 'particularly challenging' conditions for 2QFY25, resulting in 2Q guidance falling c.13%short of consensus (and our) adjusted net income expectations. This weak 2Q invariably places additional weight on 2H25, which includes a seasonally weaker December period. With management reiterating FY25 adjusted net income guidance of U$630-700m, we set our forecast at the lower end of the range, acknowledging that lower interest rates will be a positive, when they occur. We retain our Add rating.

The broker has retained its add rating with an improved price target of $57.25.

Healthco Healthcare and Wellness REIT (ASX: HCW) 

Finally, Morgans was pleased with this health and wellness focused property company's results. It explains:

The FY24 result saw portfolio metrics remain stable (cash collection 100%; occupancy 99%; and WALE +12 years). NTA $1.64. Asset recycling has been a focus during FY24 and management has flagged it will continue to look at asset sales in FY25, although no further detail around the quantum of divestments at this stage. We retain our Add rating.

Morgans has retained its add rating with a trimmed price target of $1.51.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL and Challenger. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

These ASX 200 shares could rise 30% to 50%

Brokers have good things to say about these cheap shares.

Read more »

A female ASX investor looks through a magnifying glass that enlarges her eye and holds her hand to her face with her mouth open as if looking at something of great interest or surprise.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Broker Notes

10 Aussie stocks to buy in FY 2026

Let's see which shares analysts think could be buys in the upcoming financial year.

Read more »

watch
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Mum playing with her baby boy holding him on her tummy as she lays down while smiling about the Bubs share price going up today
Broker Notes

Following two unfortunate incidents, what's Macquarie's price target on Monash IVF shares?

Is Monash IVF a buying opportunity?

Read more »

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

Macquarie tips 18% return for this ASX 200 stock

The broker thinks this blue chip's profits are going to rebound in FY 2026.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Broker Notes

Bell Potter names more of the best ASX 200 shares to buy in FY26

These shares are among the best to buy in the new financial year according to its analysts.

Read more »

Suncorp share price Businessman cheering and smiling on smartphone
Broker Notes

5 ASX 200 shares for smart investors to buy in July

Brokers think these shares could be in the buy zone ahead of the new month.

Read more »